Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?

1.

Dougherty CJ, Ichim TE, Liu L, Reznik G, Min WP, Ghochikyan A, Agadjanyan MG, Reznik BN: Selective apoptosis of breast cancer cells by siRNA targeting of BORIS. Biochem Biophys Res Commun. 2008, 370: 109-112.PubMed

2.

Loukinov D, Ghochikyan A, Mkrtichyan M, Ichim TE, Lobanenkov VV, Cribbs DH, Agadjanyan MG: Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem. 2006, 98: 1037-1043.PubMed

3.

Ghochikyan A, Mkrtichyan M, Loukinov D, Mamikonyan G, Pack SD, Movsesyan N, Ichim TE, Cribbs DH, Lobanenkov VV, Agadjanyan MG: Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol. 2007, 178: 566-573.PubMedCentralPubMed

4.

Mkrtichyan M, Ghochikyan A, Loukinov D, Davtyan H, Ichim TE, Cribbs DH, Lobanenkov VV, Agadjanyan MG: DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice. Gene Ther. 2008, 15: 61-64.PubMedCentralPubMed

5.

Ichim TE, Zhong Z, Kaushal S, Zheng X, Ren X, Hao X, Joyce JA, Hanley HH, Riordan NH, Koropatnick J: Exosomes as a tumor immune escape mechanism: possible therapeutic implications. J Transl Med. 2008, 6: 37-PubMedCentralPubMed

6.

Marleau AM, Lipton JH, Riordan NH, Ichim TE: Therapeutic use of Aldara in chronic myeloid leukemia. J Transl Med. 2007, 5: 4-PubMedCentralPubMed

7.

Ichim TE, Popov IA, Riordan NH, Izadi H, Zhong Z, Yijian L, Sher S, Oleinik EK: A novel method of modifying immune responses by vaccination with lipiodol-siRNA mixtures. J Transl Med. 2006, 4: 2-PubMedCentralPubMed

8.

Zhong Z, Kusznieruk KP, Popov IA, Riordan NH, Izadi H, Yijian L, Sher S, Szczurko OM, Agadjanyan MG, Tullis RH: Induction of antitumor immunity through xenoplacental immunization. J Transl Med. 2006, 4: 22-PubMedCentralPubMed

9.

Han X, Meng X, Yin Z, Rogers A, Zhong J, Rillema P, Jackson JA, Ichim TE, Minev B, Carrier E: Inhibition of intracranial glioma growth by endometrial regenerative cells. Cell Cycle. 2009, 8: 606-610.PubMed

10.

Levenson SM: Ascorbic acid r, thiamin, and nicotinic acid in relation to severe injury, hemorrhage, and infection in the human. Ann Surg. 1946, 124: 840-856.PubMedCentral

11.

Cameron E, Campbell A: The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact. 1974, 9: 285-315.PubMed

12.

Yeom CH, Jung GC, Song KJ: Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration. J Korean Med Sci. 2007, 22: 7-11.PubMedCentralPubMed

13.

Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA. 1976, 73: 3685-3689.PubMedCentralPubMed

14.

Cameron and Pauling PNASUSAS-Saitstocropos.

15.

Murata A, Morishige F, Yamaguchi H: Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int J Vitam Nutr Res Suppl. 1982, 23: 103-113.PubMed

16.

Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, Rubin J, Frytak S: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med. 1979, 301: 687-690.PubMed

17.

Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Ames MM: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med. 1985, 312: 137-141.PubMed

18.

Duconge J, Miranda-Massari JR, Gonzalez MJ, Jackson JA, Warnock W, Riordan NH: Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate. P R Health Sci J. 2008, 27: 7-19.PubMed

19.

Duconge J, Miranda-Massari JR, Gonzalez MJ, Taylor PR, Riordan HD, Riordan NH, Casciari JJ, Alliston K: Vitamin C pharmacokinetics after continuous infusion in a patient with prostate cancer. Ann Pharmacother. 2007, 41: 1082-1083.PubMed

20.

Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA, Levine M: Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004, 140: 533-537.PubMed

21.

Riordan NH, Riordan HD, Meng X, Li Y, Jackson JA: Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Med Hypotheses. 1995, 44: 207-213.PubMed

22.

Verrax J, Calderon PB: Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med. 2009, 47: 32-40.PubMed

23.

Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, Levine M: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA. 2008, 105: 11105-11109.PubMedCentralPubMed

24.

Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, Choyke PL, Pooput C, Kirk KL, Buettner GR, Levine M: Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA. 2007, 104: 8749-8754.PubMedCentralPubMed

25.

Padayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, Levine M: Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One. 5: e11414-

26.

Study of High-Dose Intravenous (IV) Vitamin C Treatment in Patients With Solid Tumors. [http://www.clinicaltrials.gov/ct2/show/NCT00441207]

27.

Vitamin C as an Anti-cancer Drug. [http://www.clinicaltrials.gov/ct2/show/NCT01080352]

28.

Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL). [http://www.clinicaltrials.gov/ct2/show/NCT00626444]

29.

Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease. [http://www.clinicaltrials.gov/ct2/show/NCT01125449]

30.

Trial of Chemotherapy Plus Intravenous Vitamin C in Patients With Advanced Cancer for Whom Chemotherapy Alone is Only Marginally Effective. [http://www.clinicaltrials.gov/ct2/show/NCT01050621]

31.

Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer. [http://www.clinicaltrials.gov/ct2/show/NCT00954525]

32.

Polterauer S, Grimm C, Seebacher V, Rahhal J, Tempfer C, Reinthaller A, Hefler L: The inflammation-based Glasgow Prognostic Score predicts survival in patients with cervical cancer. Int J Gynecol Cancer. 20: 1052-1057.

33.

Argiles JM, Busquets S, Toledo M, Lopez-Soriano FJ: The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care. 2009, 3: 263-268.PubMed

34.

Stephens NA, Skipworth RJ, Fearon KC: Cachexia, survival and the acute phase response. Curr Opin Support Palliat Care. 2008, 2: 267-274.PubMed

35.

Deans C, Wigmore SJ: Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care. 2005, 8: 265-269.PubMed

36.

Roxburgh CS, McMillan DC: Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 6: 149-163.

37.

Lamb GW, McArdle PA, Ramsey S, McNichol AM, Edwards J, Aitchison M, McMillan DC: The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU Int. 2008, 102: 756-761.PubMed

38.

Ibrahim S, Claxton DF: SIRS criteria in prediction of septic shock in hospitalized patients with hematologic malignancies. Cancer Biol Ther. 2009, 8: 1101-PubMed

39.

Nomura S, Kagawa H, Ozaki Y, Nagahama M, Yoshimura C, Fukuhara S: Relationship between platelet activation and cytokines in systemic inflammatory response syndrome patients with hematological malignancies. Thromb Res. 1999, 95: 205-213.PubMed

40.

Regazzoni CJ, Khoury M, Irrazabal C, Myburg C, Galvalisi NR, O'Flaherty M, Sarquis SG, Poderoso JJ: Neutropenia and the development of the systemic inflammatory response syndrome. Intensive Care Med. 2003, 29: 135-138.PubMed

41.

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992, 20: 864-874.

42.

Systemic Inflammatory Response Syndrome (SIRS) Prognosis. [http://www.youtube.com/watch?v=p2rEJC7He6g]

43.

de Jong HK, van der Poll T, Wiersinga WJ: The systemic pro-inflammatory response in sepsis. J Innate Immun. 2: 422-430.

44.

Gando S: Disseminated intravascular coagulation in trauma patients. Semin Thromb Hemost. 2001, 27: 585-592.PubMed

45.

Guo RF, Ward PA: C5a, a therapeutic target in sepsis. Recent Pat Antiinfect Drug Discov. 2006, 1: 57-65.PubMed

46.

Silasi-Mansat R, Zhu H, Popescu NI, Peer G, Sfyroera G, Magotti P, Ivanciu L, Lupu C, Mollnes TE, Taylor FB: Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood. 116: 1002-1010.

47.

Person AK, Kontoyiannis DP, Alexander BD: Fungal infections in transplant and oncology patients. Infect Dis Clin North Am. 24: 439-459.

48.

Kiehn TE: Bacteremia and fungemia in the immunocompromised patient. Eur J Clin Microbiol Infect Dis. 1989, 8: 832-837.PubMed

49.

Tisdale MJ: Cancer cachexia. Curr Opin Gastroenterol. 26: 26-146.

50.

Gelin J, Moldawer LL, Lonnroth C, Sherry B, Chizzonite R, Lundholm K: Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res. 1991, 51: 415-421.PubMed

51.

Cahlin C, Korner A, Axelsson H, Wang W, Lundholm K, Svanberg E: Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res. 2000, 60: 5488-5493.PubMed

52.

Ely EW, Bernard GR, Vincent JL: Activated protein C for severe sepsis. N Engl J Med. 2002, 347: 1035-1036.PubMed

53.

Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC, Spapen HD, Riess H, Basson B, Johnson G, Kinasewitz GT: Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost. 2003, 90: 642-653.PubMed

54.

Minhas N, Xue M, Fukudome K, Jackson CJ: Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function. FASEB J. 24: 24-873.

55.

Loubele ST, Spronk HM, Ten Cate H: Activated protein C: a promising drug with multiple effects?. Mini Rev Med Chem. 2009, 9: 620-626.PubMed

56.

Poole D, Bertolini G, Garattini S: Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis. Lancet Infect Dis. 2009, 9: 67-72.PubMed

57.

Pastores SM, Papadopoulos E, van den Brink M, Alicea M, Halpern NA: Septic shock and multiple organ failure after hematopoietic stem cell transplantation: treatment with recombinant human activated protein C. Bone Marrow Transplant. 2002, 30: 131-134.PubMed

58.

Cristofaro P, Opal SM: The Toll-like receptors and their role in septic shock. Expert Opin Ther Targets. 2003, 7: 603-612.PubMed

59.

Treutiger CJ, Mullins GE, Johansson AS, Rouhiainen A, Rauvala HM, Erlandsson-Harris H, Andersson U, Yang H, Tracey KJ, Andersson J, Palmblad JE: High mobility group 1 B-box mediates activation of human endothelium. J Intern Med. 2003, 254: 375-385.PubMed

60.

Lv B, Wang H, Tang Y, Fan Z, Xiao X, Chen F: High-mobility group box 1 protein induces tissue factor expression in vascular endothelial cells via activation of NF-kappaB and Egr-1. Thromb Haemost. 2009, 102: 352-359.PubMedCentralPubMed

61.

Wada H, Wakita Y, Shiku H: Tissue factor expression in endothelial cells in health and disease. Blood Coagul Fibrinolysis. 1995, 6 (Suppl 1): S26-31.PubMed

62.

Levi M: The coagulant response in sepsis and inflammation. Hamostaseologie. 30: 10-12. 14-16

63.

Munro JM, Pober JS, Cotran RS: Recruitment of neutrophils in the local endotoxin response: association with de novo endothelial expression of endothelial leukocyte adhesion molecule-1. Lab Invest. 1991, 64: 295-299.PubMed

64.

Lippi G, Ippolito L, Cervellin G: Disseminated intravascular coagulation in burn injury. Semin Thromb Hemost. 36: 36-429.

65.

Lau CL, Zhao Y, Kim J, Kron IL, Sharma A, Yang Z, Laubach VE, Linden J, Ailawadi G, Pinsky DJ: Enhanced fibrinolysis protects against lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 2009, 137: 1241-1248.PubMedCentralPubMed

66.

Levi M, Schouten M, van der Poll T: Sepsis, coagulation, and antithrombin: old lessons and new insights. Semin Thromb Hemost. 2008, 34: 742-746.PubMed

67.

Shapiro N, Schuetz P, Yano K, Sorasaki M, Parikh SM, Jones AE, Trzeciak S, Ngo L, Aird WC: The association of endothelial cell signaling, severity of illness, and organ dysfunction in sepsis. Crit Care. 14: R182-

68.

Druey KM, Greipp PR: Narrative review: the systemic capillary leak syndrome. Ann Intern Med. 153: 153-90.

69.

Dejana E, Orsenigo F, Lampugnani MG: The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci. 2008, 121: 2115-2122.PubMed

70.

Azevedo LC, Janiszewski M, Soriano FG, Laurindo FR: Redox mechanisms of vascular cell dysfunction in sepsis. Endocr Metab Immune Disord Drug Targets. 2006, 6: 159-164.PubMed

71.

Okajima K: Prevention of endothelial cell injury by activated protein C: the molecular mechanism(s) and therapeutic implications. Curr Vasc Pharmacol. 2004, 2: 125-133.PubMed

72.

Andersson U, Tracey KJ: HMGB1 in sepsis. Scand J Infect Dis. 2003, 35: 577-584.PubMed

73.

Strassheim D, Park JS, Abraham E: Sepsis: current concepts in intracellular signaling. Int J Biochem Cell Biol. 2002, 34: 1527-1533.PubMed

74.

ten Cate H, Schoenmakers SH, Franco R, Timmerman JJ, Groot AP, Spek CA, Reitsma PH: Microvascular coagulopathy and disseminated intravascular coagulation. Crit Care Med. 2001, 29: S95-97. discussion S97-98PubMed

75.

Hawiger J: Innate immunity and inflammation: a transcriptional paradigm. Immunol Res. 2001, 23: 99-109.PubMed

76.

Edgington TS, Mackman N, Fan ST, Ruf W: Cellular immune and cytokine pathways resulting in tissue factor expression and relevance to septic shock. Nouv Rev Fr Hematol. 1992, 34 (Suppl): S15-27.PubMed

77.

Mukaida N, Ishikawa Y, Ikeda N, Fujioka N, Watanabe S, Kuno K, Matsushima K: Novel insight into molecular mechanism of endotoxin shock: biochemical analysis of LPS receptor signaling in a cell-free system targeting NF-kappaB and regulation of cytokine production/action through beta2 integrin in vivo. J Leukoc Biol. 1996, 59: 145-151.PubMed

78.

Liu SF, Malik AB: NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol. 2006, 290: L622-L645.PubMed

79.

Ulfhammer E, Larsson P, Karlsson L, Hrafnkelsdottir T, Bokarewa M, Tarkowski A, Jern S: TNF-alpha mediated suppression of tissue type plasminogen activator expression in vascular endothelial cells is NF-kappaB- and p38 MAPK-dependent. J Thromb Haemost. 2006, 4: 1781-1789.PubMed

80.

Xu H, Ye X, Steinberg H, Liu SF: Selective blockade of endothelial NF-kappaB pathway differentially affects systemic inflammation and multiple organ dysfunction and injury in septic mice. J Pathol. 220: 220-490.

81.

Ding J, Song D, Ye X, Liu SF: A pivotal role of endothelial-specific NF-kappaB signaling in the pathogenesis of septic shock and septic vascular dysfunction. J Immunol. 2009, 183: 4031-4038.PubMedCentralPubMed

82.

Song D, Ye X, Xu H, Liu SF: Activation of endothelial intrinsic NF-{kappa}B pathway impairs protein C anticoagulation mechanism and promotes coagulation in endotoxemic mice. Blood. 2009, 114: 2521-2529.PubMedCentralPubMed

83.

Grinnell BW, Joyce D: Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis. Crit Care Med. 2001, 29: S53-60. discussion S60-51PubMed

84.

Brueckmann M, Hoffmann U, De Rossi L, Weiler HM, Liebe V, Lang S, Kaden JJ, Borggrefe M, Haase KK, Huhle G: Activated protein C inhibits the release of macrophage inflammatory protein-1-alpha from THP-1 cells and from human monocytes. Cytokine. 2004, 26: 106-113.PubMed

85.

Cheng T, Liu D, Griffin JH, Fernandez JA, Castellino F, Rosen ED, Fukudome K, Zlokovic BV: Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med. 2003, 9: 338-342.PubMed

86.

van Hinsbergh VW, Bertina RM, van Wijngaarden A, van Tilburg NH, Emeis JJ, Haverkate F: Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood. 1985, 65: 444-451.PubMed

87.

Sakata Y, Curriden S, Lawrence D, Griffin JH, Loskutoff DJ: Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci USA. 1985, 82: 1121-1125.PubMedCentralPubMed

88.

Joyce DE, Grinnell BW: Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med. 2002, 30: S288-293.PubMed

89.

Brueckmann M, Hoffmann U, Dvortsak E, Lang S, Kaden JJ, Borggrefe M, Haase KK: Drotrecogin alfa (activated) inhibits NF-kappa B activation and MIP-1-alpha release from isolated mononuclear cells of patients with severe sepsis. Inflamm Res. 2004, 53: 528-533.PubMed

90.

Heitzer T, Just H, Munzel T: Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation. 1996, 94: 6-9.PubMed

91.

Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS: Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation. 1999, 99: 1156-1160.PubMed

92.

Timimi FK, Ting HH, Haley EA, Roddy MA, Ganz P, Creager MA: Vitamin C improves endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1998, 31: 552-557.PubMed

93.

Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA: Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 1996, 97: 22-28.PubMedCentralPubMed

94.

Solzbach U, Hornig B, Jeserich M, Just H: Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation. 1997, 96: 1513-1519.PubMed

95.

Gao Y: The multiple actions of NO. Pflugers Arch. 459: 459-829.

96.

Jackson WF: The endothelium-derived relaxing factor. J Reconstr Microsurg. 1989, 5: 263-271.PubMed

97.

De Cruz SJ, Kenyon NJ, Sandrock CE: Bench-to-bedside review: the role of nitric oxide in sepsis. Expert Rev Respir Med. 2009, 3: 511-521.PubMed

98.

Tyml K, Li F, Wilson JX: Septic impairment of capillary blood flow requires nicotinamide adenine dinucleotide phosphate oxidase but not nitric oxide synthase and is rapidly reversed by ascorbate through an endothelial nitric oxide synthase-dependent mechanism. Crit Care Med. 2008, 36: 2355-2362.PubMedCentralPubMed

99.

Naseem KM: The role of nitric oxide in cardiovascular diseases. Mol Aspects Med. 2005, 26: 33-65.PubMed

100.

Parratt JR: Nitric oxide in sepsis and endotoxaemia. J Antimicrob Chemother. 1998, 41 (Suppl A): 31-39.PubMed

101.

Wu F, Tyml K, Wilson JX: Ascorbate inhibits iNOS expression in endotoxin- and IFN gamma-stimulated rat skeletal muscle endothelial cells. FEBS Lett. 2002, 520: 122-126.PubMed

102.

Wu F, Wilson JX, Tyml K: Ascorbate inhibits iNOS expression and preserves vasoconstrictor responsiveness in skeletal muscle of septic mice. Am J Physiol Regul Integr Comp Physiol. 2003, 285: R50-56.PubMed

103.

Ulker S, McKeown PP, Bayraktutan U: Vitamins reverse endothelial dysfunction through regulation of eNOS and NAD(P)H oxidase activities. Hypertension. 2003, 41: 534-539.PubMed

104.

Peluffo G, Calcerrada P, Piacenza L, Pizzano N, Radi R: Superoxide-mediated inactivation of nitric oxide and peroxynitrite formation by tobacco smoke in vascular endothelium: studies in cultured cells and smokers. Am J Physiol Heart Circ Physiol. 2009, 296: H1781-1792.PubMedCentralPubMed

105.

May JM, Qu ZC, Li X: Ascorbic acid blunts oxidant stress due to menadione in endothelial cells. Arch Biochem Biophys. 2003, 411: 136-144.PubMed

106.

Heller R, Munscher-Paulig F, Grabner R, Till U: L-Ascorbic acid potentiates nitric oxide synthesis in endothelial cells. J Biol Chem. 1999, 274: 8254-8260.PubMed

107.

Nakai K, Urushihara M, Kubota Y, Kosaka H: Ascorbate enhances iNOS activity by increasing tetrahydrobiopterin in RAW 264.7 cells. Free Radic Biol Med. 2003, 35: 929-937.PubMed

108.

d'Uscio LV, Milstien S, Richardson D, Smith L, Katusic ZS: Long-term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ Res. 2003, 92: 88-95.PubMed

109.

Toth M, Kukor Z, Valent S: Chemical stabilization of tetrahydrobiopterin by L-ascorbic acid: contribution to placental endothelial nitric oxide synthase activity. Mol Hum Reprod. 2002, 8: 271-280.PubMed

110.

Patel KB, Stratford MR, Wardman P, Everett SA: Oxidation of tetrahydrobiopterin by biological radicals and scavenging of the trihydrobiopterin radical by ascorbate. Free Radic Biol Med. 2002, 32: 203-211.PubMed

111.

Stone KJ, Townsley BH: The effect of L-ascorbate on catecholamine biosynthesis. Biochem J. 1973, 131: 611-613.PubMedCentralPubMed

112.

Huang A, Vita JA, Venema RC, Keaney JF: Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. J Biol Chem. 2000, 275: 17399-17406.PubMed

113.

Schmidt TS, Alp NJ: Mechanisms for the role of tetrahydrobiopterin in endothelial function and vascular disease. Clin Sci (Lond). 2007, 113: 47-63.

114.

Keel M, Trentz O: Pathophysiology of polytrauma. Injury. 2005, 36: 691-709.PubMed

115.

Rossig L, Hoffmann J, Hugel B, Mallat Z, Haase A, Freyssinet JM, Tedgui A, Aicher A, Zeiher AM, Dimmeler S: Vitamin C inhibits endothelial cell apoptosis in congestive heart failure. Circulation. 2001, 104: 2182-2187.PubMed

116.

Haendeler J, Zeiher AM, Dimmeler S: Vitamin C and E prevent lipopolysaccharide-induced apoptosis in human endothelial cells by modulation of Bcl-2 and Bax. Eur J Pharmacol. 1996, 317: 407-411.PubMed

117.

Saeed RW, Peng T, Metz CN: Ascorbic acid blocks the growth inhibitory effect of tumor necrosis factor-alpha on endothelial cells. Exp Biol Med (Maywood). 2003, 228: 855-865.

118.

Fiorito C, Rienzo M, Crimi E, Rossiello R, Balestrieri ML, Casamassimi A, Muto F, Grimaldi V, Giovane A, Farzati B: Antioxidants increase number of progenitor endothelial cells through multiple gene expression pathways. Free Radic Res. 2008, 42: 754-762.PubMed

119.

Mo SJ, Son EW, Rhee DK, Pyo S: Modulation of TNF-alpha-induced ICAM-1 expression, NO and H2O2 production by alginate, allicin and ascorbic acid in human endothelial cells. Arch Pharm Res. 2003, 26: 244-251.PubMed

120.

Martin WJ: Neutrophils kill pulmonary endothelial cells by a hydrogen-peroxide-dependent pathway. An in vitro model of neutrophil-mediated lung injury. Am Rev Respir Dis. 1984, 130: 209-213.PubMed

121.

Chen YH, Lin SJ, Chen YL, Liu PL, Chen JW: Anti-inflammatory effects of different drugs/agents with antioxidant property on endothelial expression of adhesion molecules. Cardiovasc Hematol Disord Drug Targets. 2006, 6: 279-304.PubMed

122.

May JM, Qu ZC: Ascorbic acid prevents increased endothelial permeability caused by oxidized low density lipoprotein. Free Radic Res. 44: 44-1359.

123.

Wilson JX: Mechanism of action of vitamin C in sepsis: ascorbate modulates redox signaling in endothelium. Biofactors. 2009, 35: 5-13.PubMedCentralPubMed

124.

Utoguchi N, Ikeda K, Saeki K, Oka N, Mizuguchi H, Kubo K, Nakagawa S, Mayumi T: Ascorbic acid stimulates barrier function of cultured endothelial cell monolayer. J Cell Physiol. 1995, 163: 393-399.PubMed

125.

Bowie A, O'Neill LA: Vitamin C inhibits NF kappa B activation in endothelial cells. Biochem Soc Trans. 1997, 25: 131S-PubMed

126.

Carcamo JM, Pedraza A, Borquez-Ojeda O, Golde DW: Vitamin C suppresses TNF alpha-induced NF kappa B activation by inhibiting I kappa B alpha phosphorylation. Biochemistry. 2002, 41: 12995-13002.PubMed

127.

Bowie AG, O'Neill LA: Vitamin C inhibits NF-kappa B activation by TNF via the activation of p38 mitogen-activated protein kinase. J Immunol. 2000, 165: 7180-7188.PubMed

128.

Rodriguez-Porcel M, Lerman LO, Holmes DR, Richardson D, Napoli C, Lerman A: Chronic antioxidant supplementation attenuates nuclear factor-kappa B activation and preserves endothelial function in hypercholesterolemic pigs. Cardiovasc Res. 2002, 53: 1010-1018.PubMed

129.

Chade AR, Rodriguez-Porcel M, Herrmann J, Zhu X, Grande JP, Napoli C, Lerman A, Lerman LO: Antioxidant intervention blunts renal injury in experimental renovascular disease. J Am Soc Nephrol. 2004, 15: 958-966.PubMed

130.

Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, Park JB, Lazarev A, Graumlich JF, King J, Cantilena LR: Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA. 1996, 93: 3704-3709.PubMedCentralPubMed

131.

Hathcock JN, Azzi A, Blumberg J, Bray T, Dickinson A, Frei B, Jialal I, Johnston CS, Kelly FJ, Kraemer K: Vitamins E and C are safe across a broad range of intakes. Am J Clin Nutr. 2005, 81: 736-745.PubMed

132.

Eskurza I, Monahan KD, Robinson JA, Seals DR: Effect of acute and chronic ascorbic acid on flow-mediated dilatation with sedentary and physically active human ageing. J Physiol. 2004, 556: 315-324.PubMedCentralPubMed

133.

McGregor GP, Biesalski HK: Rationale and impact of vitamin C in clinical nutrition. Curr Opin Clin Nutr Metab Care. 2006, 9: 697-703.PubMed

134.

Schorah CJ, Downing C, Piripitsi A, Gallivan L, Al-Hazaa AH, Sanderson MJ, Bodenham A: Total vitamin C, ascorbic acid, and dehydroascorbic acid concentrations in plasma of critically ill patients. Am J Clin Nutr. 1996, 63: 760-765.PubMed

135.

Sinclair AJ, Taylor PB, Lunec J, Girling AJ, Barnett AH: Low plasma ascorbate levels in patients with type 2 diabetes mellitus consuming adequate dietary vitamin C. Diabet Med. 1994, 11: 893-898.PubMed

136.

Du WD, Yuan ZR, Sun J, Tang JX, Cheng AQ, Shen DM, Huang CJ, Song XH, Yu XF, Zheng SB: Therapeutic efficacy of high-dose vitamin C on acute pancreatitis and its potential mechanisms. World J Gastroenterol. 2003, 9: 2565-2569.PubMed

137.

Bakaev VV, Duntau AP: Ascorbic acid in blood serum of patients with pulmonary tuberculosis and pneumonia. Int J Tuberc Lung Dis. 2004, 8: 263-266.PubMed

138.

Maggio D, Barabani M, Pierandrei M, Polidori MC, Catani M, Mecocci P, Senin U, Pacifici R, Cherubini A: Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J Clin Endocrinol Metab. 2003, 88: 1523-1527.PubMed

139.

Lunec J, Blake DR: The determination of dehydroascorbic acid and ascorbic acid in the serum and synovial fluid of patients with rheumatoid arthritis (RA). Free Radic Res Commun. 1985, 1: 31-39.PubMed

140.

Fain O, Mathieu E, Thomas M: Scurvy in patients with cancer. BMJ. 1998, 316: 1661-1662.PubMedCentralPubMed

141.

Mayland CR, Bennett MI, Allan K: Vitamin C deficiency in cancer patients. Palliat Med. 2005, 19: 17-20.PubMed

142.

Bodansky O, Wroblewski F, Markardt B: Concentrations of ascorbic acid in plasma and white blood cells of patients with cancer and noncancerous chronic disease. Cancer. 1952, 5: 678-684.PubMed

143.

Butcher RG, Chayen J: Oxidation of L-ascorbic acid by cells of carcinoma of the human cervix. Nature. 1965, 207: 992-993.PubMed

144.

Fraenkel-Conrat J, Stoy T, Tsai SF: Investigation of ascorbic acid levels in blood of cancer patients compared to normal subjects. Mo Med. 1967, 64: 1001-1002.PubMed

145.

Anthony HM, Schorah CJ: Severe hypovitaminosis C in lung-cancer patients: the utilization of vitamin C in surgical repair and lymphocyte-related host resistance. Br J Cancer. 1982, 46: 354-367.PubMedCentralPubMed

146.

Gupta A, Bhatt ML, Misra MK: Lipid peroxidation and antioxidant status in head and neck squamous cell carcinoma patients. Oxid Med Cell Longev. 2009, 2: 68-72.PubMedCentralPubMed

147.

Long CL, Maull KI, Krishnan RS, Laws HL, Geiger JW, Borghesi L, Franks W, Lawson TC, Sauberlich HE: Ascorbic acid dynamics in the seriously ill and injured. J Surg Res. 2003, 109: 144-148.PubMed

148.

Kuiper C, Molenaar IG, Dachs GU, Currie MJ, Sykes PH, Vissers MC: Low ascorbate levels are associated with increased hypoxia-inducible factor-1 activity and an aggressive tumor phenotype in endometrial cancer. Cancer Res. 70: 70-5749.

149.

Ghezzi F, Cromi A, Siesto G, Giudici S, Serati M, Formenti G, Franchi M: Prognostic significance of preoperative plasma fibrinogen in endometrial cancer. Gynecol Oncol. 119: 119-309.

150.

Tang L, Liu K, Wang J, Wang C, Zhao P, Liu J: High preoperative plasma fibrinogen levels are associated with distant metastases and impaired prognosis after curative resection in patients with colorectal cancer. J Surg Oncol. 102: 102-428.

151.

Polterauer S, Grimm C, Seebacher V, Concin N, Marth C, Tomovski C, Husslein H, Leipold H, Hefler-Frischmuth K, Tempfer C: Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist. 2009, 14: 979-985.PubMed

152.

Zhu WL, Fan BL, Liu DL, Zhu WX: Abnormal expression of fibrinogen gamma (FGG) and plasma level of fibrinogen in patients with hepatocellular carcinoma. Anticancer Res. 2009, 29: 2531-2534.PubMed

153.

Polterauer S, Seebacher V, Hefler-Frischmuth K, Grimm C, Heinze G, Tempfer C, Reinthaller A, Hefler L: Fibrinogen plasma levels are an independent prognostic parameter in patients with cervical cancer. Am J Obstet Gynecol. 2009, 200: e641-647.

154.

Guo Q, Zhang B, Dong X, Xie Q, Guo E, Huang H, Wu Y: Elevated levels of plasma fibrinogen in patients with pancreatic cancer: possible role of a distant metastasis predictor. Pancreas. 2009, 38: e75-79.PubMed

155.

Takeuchi H, Ikeuchi S, Kitagawa Y, Shimada A, Oishi T, Isobe Y, Kubochi K, Kitajima M, Matsumoto S: Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol. 2007, 22: 2222-2227.PubMed

156.

Lukaszewicz-Zajac M, Mroczko B, Gryko M, Kedra B, Szmitkowski M: Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer. Clin Exp Med. 2010,

157.

Kanz R, Vukovich T, Vormittag R, Dunkler D, Ay C, Thaler J, Haselbock J, Scheithauer W, Zielinski C, Pabinger I: Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost. 2011, 9 (1): 57-63.PubMed

158.

Kocsis J, Meszaros T, Madaras B, Toth EK, Kamondi S, Gal P, Varga L, Prohaszka Z, Fust G: High levels of acute phase proteins and soluble 70 kDa heat shock proteins are independent and additive risk factors for mortality in colorectal cancer. Cell Stress Chaperones. 2011, 16 (1): 49-55. Epub 2010 Aug 22PubMedCentralPubMed

159.

Prins RC, Rademacher BL, Mongoue-Tchokote S, Alumkal JJ, Graff JN, Eilers KM, Beer TM: C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results. Urol Oncol. 2010,

160.

Wang CS, Sun CF: C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J. 2009, 32: 471-482.PubMed

161.

Schroecksnadel K, Frick B, Fiegl M, Winkler C, Denz HA, Fuchs D: Hyperhomocysteinaemia and immune activation in patients with cancer. Clin Chem Lab Med. 2007, 45: 47-53.PubMed

162.

Miyata Y, Koga S, Nishikido M, Noguchi M, Kanda S, Hayashi T, Saito Y, Kanetake H: Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma. Urology. 2001, 58: 161-164.PubMed

163.

Song MK, Chung JS, Seol YM, Shin HJ, Choi YJ, Cho GJ: Elevation of serum ferritin is associated with the outcome of patients with newly diagnosed multiple myeloma. Korean J Intern Med. 2009, 24: 368-373.PubMedCentralPubMed

164.

Singh KJ, Singh SK, Suri A, Vijjan V, Goswami AK, Khullar M: Serum ferritin in renal cell carcinoma: effect of tumor size, volume grade, and stage. Indian J Cancer. 2005, 42: 197-200.PubMed

165.

Garaventa A, Boni L, Lo Piccolo MS, Tonini GP, Gambini C, Mancini A, Tonegatti L, Carli M, di Montezemolo LC, Di Cataldo A: Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors. Ann Oncol. 2002, 13: 956-964.PubMed

166.

Sucher R, Schroecksnadel K, Weiss G, Margreiter R, Fuchs D, Brandacher G: Neopterin, a prognostic marker in human malignancies. Cancer Lett. 287: 287-13.

167.

Melichar B, Solichova D, Freedman RS: Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int J Gynecol Cancer. 2006, 16: 240-252.PubMed

168.

Murr C, Fuith LC, Widner B, Wirleitner B, Baier-Bitterlich G, Fuchs D: Increased neopterin concentrations in patients with cancer: indicator of oxidative stress?. Anticancer Res. 1999, 19: 1721-1728.PubMed

169.

Ferroni P, Palmirotta R, Martini F, Riondino S, Savonarola A, Spila A, Ciatti F, Sini V, Mariotti S, Del Monte G: Determinants of homocysteine levels in colorectal and breast cancer patients. Anticancer Res. 2009, 29: 4131-4138.PubMed

170.

Almadori G, Bussu F, Galli J, Cadoni G, Zappacosta B, Persichilli S, Minucci A, Giardina B, Maurizi M: Serum levels of folate, homocysteine, and vitamin B12 in head and neck squamous cell carcinoma and in laryngeal leukoplakia. Cancer. 2005, 103: 284-292.PubMed

171.

Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF: Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992, 52: 3317-3322.PubMed

172.

Salzman R, Pacal L, Tomandl J, Kankova K, Tothova E, Gal B, Kostrica R, Salzman P: Elevated malondialdehyde correlates with the extent of primary tumor and predicts poor prognosis of oropharyngeal cancer. Anticancer Res. 2009, 29: 4227-4231.PubMed

173.

Arsova-Sarafinovska Z, Eken A, Matevska N, Erdem O, Sayal A, Savaser A, Banev S, Petrovski D, Dzikova S, Georgiev V: Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer. Clin Biochem. 2009, 42: 1228-1235.PubMed

174.

Patel BP, Rawal UM, Dave TK, Rawal RM, Shukla SN, Shah PM, Patel PS: Lipid peroxidation, total antioxidant status, and total thiol levels predict overall survival in patients with oral squamous cell carcinoma. Integr Cancer Ther. 2007, 6: 365-372.PubMed

175.

Ray G, Batra S, Shukla NK, Deo S, Raina V, Ashok S, Husain SA: Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Res Treat. 2000, 59: 163-170.PubMed

176.

Fain O, Paries J, Jacquart B, Le Moel G, Kettaneh A, Stirnemann J, Heron C, Sitbon M, Taleb C, Letellier E: Hypovitaminosis C in hospitalized patients. Eur J Intern Med. 2003, 14: 419-425.PubMed

177.

Kubota Y, Moriyama Y, Yamagishi K, Tanigawa T, Noda H, Yokota K, Harada M, Inagawa M, Oshima M, Sato S, Iso H: Serum vitamin C concentration and hs-CRP level in middle-aged Japanese men and women. Atherosclerosis. 208: 208-496.

178.

Block G, Jensen CD, Dalvi TB, Norkus EP, Hudes M, Crawford PB, Holland N, Fung EB, Schumacher L, Harmatz P: Vitamin C treatment reduces elevated C-reactive protein. Free Radic Biol Med. 2009, 46: 70-77.PubMedCentralPubMed

179.

Mayland C, Allen KR, Degg TJ, Bennet M: Micronutrient concentrations in patients with malignant disease: effect of the inflammatory response. Ann Clin Biochem. 2004, 41: 138-141.PubMed

180.

Kaehler J, Koeke K, Karstens M, Schneppenheim R, Meinertz T, Heitzer T: Impaired capacity for acute endogenous fibrinolysis in smokers is restored by ascorbic acid. Free Radic Biol Med. 2008, 44: 315-321.PubMed

181.

Korantzopoulos P, Kolettis TM, Kountouris E, Dimitroula V, Karanikis P, Pappa E, Siogas K, Goudevenos JA: Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. Int J Cardiol. 2005, 102: 321-326.PubMed

182.

Bohm F, Settergren M, Pernow J: Vitamin C blocks vascular dysfunction and release of interleukin-6 induced by endothelin-1 in humans in vivo. Atherosclerosis. 2007, 190: 408-415.PubMed

183.

Murr C, Winklhofer-Roob BM, Schroecksnadel K, Maritschnegg M, Mangge H, Bohm BO, Winkelmann BR, Marz W, Fuchs D: Inverse association between serum concentrations of neopterin and antioxidants in patients with and without angiographic coronary artery disease. Atherosclerosis. 2009, 202: 543-549.PubMed

184.

Doise JM, Aho LS, Quenot JP, Guilland JC, Zeller M, Vergely C, Aube H, Blettery B, Rochette L: Plasma antioxidant status in septic critically ill patients: a decrease over time. Fundam Clin Pharmacol. 2008, 22: 203-209.PubMed

185.

Borrelli E, Roux-Lombard P, Grau GE, Girardin E, Ricou B, Dayer J, Suter PM: Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Crit Care Med. 1996, 24: 392-397.PubMed

186.

Galley HF, Davies MJ, Webster NR: Ascorbyl radical formation in patients with sepsis: effect of ascorbate loading. Free Radic Biol Med. 1996, 20: 139-143.PubMed

187.

Gaut JP, Belaaouaj A, Byun J, Roberts LJ, Maeda N, Frei B, Heinecke JW: Vitamin C fails to protect amino acids and lipids from oxidation during acute inflammation. Free Radic Biol Med. 2006, 40: 1494-1501.PubMed

188.

Shen KP, Lo YC, Yang RC, Liu HW, Chen IJ, Wu BN: Antioxidant eugenosedin-A protects against lipopolysaccharide-induced hypotension, hyperglycaemia and cytokine immunoreactivity in rats and mice. J Pharm Pharmacol. 2005, 57: 117-125.PubMed

189.

Tyml K, Li F, Wilson JX: Delayed ascorbate bolus protects against maldistribution of microvascular blood flow in septic rat skeletal muscle. Crit Care Med. 2005, 33: 1823-1828.PubMed

190.

Wu F, Wilson JX, Tyml K: Ascorbate protects against impaired arteriolar constriction in sepsis by inhibiting inducible nitric oxide synthase expression. Free Radic Biol Med. 2004, 37: 1282-1289.PubMed

191.

Crimi E, Liguori A, Condorelli M, Cioffi M, Astuto M, Bontempo P, Pignalosa O, Vietri MT, Molinari AM, Sica V: The beneficial effects of antioxidant supplementation in enteral feeding in critically ill patients: a prospective, randomized, double-blind, placebo-controlled trial. Anesth Analg. 2004, 99: 857-863. table of contentsPubMed

192.

Nathens AB, Neff MJ, Jurkovich GJ, Klotz P, Farver K, Ruzinski JT, Radella F, Garcia I, Maier RV: Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. Ann Surg. 2002, 236: 814-822.PubMedCentralPubMed

193.

Tanaka H, Matsuda T, Miyagantani Y, Yukioka T, Matsuda H, Shimazaki S: Reduction of resuscitation fluid volumes in severely burned patients using ascorbic acid administration: a randomized, prospective study. Arch Surg. 2000, 135: 326-331.PubMed

194.

Deubzer B, Mayer F, Kuci Z, Niewisch M, Merkel G, Handgretinger R, Bruchelt G: H(2)O(2)-mediated cytotoxicity of pharmacologic ascorbate concentrations to neuroblastoma cells: potential role of lactate and ferritin. Cell Physiol Biochem. 25: 25-767.

195.

Gilloteaux J, Jamison JM, Neal DR, Loukas M, Doberzstyn T, Summers JL: Cell damage and death by autoschizis in human bladder (RT4) carcinoma cells resulting from treatment with ascorbate and menadione. Ultrastruct Pathol. 34: 34-140.

196.

Cullen JJ: Ascorbate induces autophagy in pancreatic cancer. Autophagy. 6: 6-421.

197.

Takemura Y, Satoh M, Satoh K, Hamada H, Sekido Y, Kubota S: High dose of ascorbic acid induces cell death in mesothelioma cells. Biochem Biophys Res Commun. 394: 394-249.

198.

Verrax J, Pedrosa RC, Beck R, Dejeans N, Taper H, Calderon PB: In situ modulation of oxidative stress: a novel and efficient strategy to kill cancer cells. Curr Med Chem. 2009, 16: 1821-1830.PubMed

199.

Fromberg A, Gutsch D, Schulze D, Vollbracht C, Weiss G, Czubayko F, Aigner A: Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemother Pharmacol. 2010,

200.

Pollard HB, Levine MA, Eidelman O, Pollard M: Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer. In Vivo. 24: 24-249.

201.

Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M: Intravenously administered vitamin C as cancer therapy: three cases. CMAJ. 2006, 174: 937-942.PubMedCentralPubMed

202.

Mikirova NA, Ichim TE, Riordan NH: Anti-angiogenic effect of high doses of ascorbic acid. J Transl Med. 2008, 6: 50-PubMedCentralPubMed

203.

Ashino H, Shimamura M, Nakajima H, Dombou M, Kawanaka S, Oikawa T, Iwaguchi T, Kawashima S: Novel function of ascorbic acid as an angiostatic factor. Angiogenesis. 2003, 6: 259-269.PubMed

204.

Mikirova NA, Casciari JJ, Riordan NH: Ascorbate inhibition of angiogenesis in aortic rings ex vivo and subcutaneous Matrigel plugs in vivo. J Angiogenes Res. 2: 2-

205.

Yeom CH, Lee G, Park JH, Yu J, Park S, Yi SY, Lee HR, Hong YS, Yang J, Lee S: High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis. J Transl Med. 2009, 7: 70-PubMedCentralPubMed

206.

Muellner MK, Schreier SM, Schmidbauer B, Moser M, Quehenberger P, Kapiotis S, Goldenberg H, Laggner H: Vitamin C inhibits NO-induced stabilization of HIF-1alpha in HUVECs. Free Radic Res. 44: 44-783.

207.

Horak P, Crawford AR, Vadysirisack DD, Nash ZM, DeYoung MP, Sgroi D, Ellisen LW: Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis. Proc Natl Acad Sci USA. 107: 4675-4680.

208.

Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, Raman V, Bhujwalla ZM, Felsher DW, Cheng L, Pevsner J: HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell. 2007, 12: 230-238.PubMedCentralPubMed

209.

Tatla S, Woodhead V, Foreman JC, Chain BM: The role of reactive oxygen species in triggering proliferation and IL-2 secretion in T cells. Free Radic Biol Med. 1999, 26: 14-24.PubMed

210.

Williams MS, Kwon J: T cell receptor stimulation, reactive oxygen species, and cell signaling. Free Radic Biol Med. 2004, 37: 1144-1151.PubMed

211.

Schwager J, Schulze J: Influence of ascorbic acid on the response to mitogens and interleukin production of porcine lymphocytes. Int J Vitam Nutr Res. 1997, 67: 10-16.PubMed

212.

Eylar E, Baez I, Navas J, Mercado C: Sustained levels of ascorbic acid are toxic and immunosuppressive for human T cells. P R Health Sci J. 1996, 15: 21-26.PubMed

213.

Huwyler T, Hirt A, Morell A: Effect of ascorbic acid on human natural killer cells. Immunol Lett. 1985, 10: 173-176.PubMed

214.

Tan PH, Sagoo P, Chan C, Yates JB, Campbell J, Beutelspacher SC, Foxwell BM, Lombardi G, George AJ: Inhibition of NF-kappa B and oxidative pathways in human dendritic cells by antioxidative vitamins generates regulatory T cells. J Immunol. 2005, 174: 7633-7644.PubMed

215.

Chen S, Yang L, Li Y: TCR zeta chain expression in T cells from patients with CML. Hematology. 2009, 14: 95-100.PubMed

216.

Kulkarni DP, Wadia PP, Pradhan TN, Pathak AK, Chiplunkar SV: Mechanisms involved in the down-regulation of TCR zeta chain in tumor versus peripheral blood of oral cancer patients. Int J Cancer. 2009, 124: 1605-1613.PubMed

217.

Gruber IV, El Yousfi S, Durr-Storzer S, Wallwiener D, Solomayer EF, Fehm T: Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients. Anticancer Res. 2008, 28: 779-784.PubMed

218.

Pignataro L, Pagani D, Brando B, Sambataro G, Scarpati B, Corsi MM: Down-regulation of zeta chain and zeta-associated protein 70 (Zap 70) expression in circulating T lymphocytes in laryngeal squamous cell carcinoma. Anal Quant Cytol Histol. 2007, 29: 57-62.PubMed

219.

Zehbe I, Schmidt M, Maeurer M, Leo C, Hockel M, Pilch H: Different T-cell receptor (TCR) zeta chain expression in cervical cancer and its precursor lesions. Zentralbl Gynakol. 2006, 128: 266-270.PubMed

220.

Ciszak L, Pawlak E, Kosmaczewska A, Potoczek S, Frydecka I: Alterations in the expression of signal-transducing CD3 zeta chain in T cells from patients with chronic inflammatory/autoimmune diseases. Arch Immunol Ther Exp (Warsz). 2007, 55: 373-386.

221.

Baniyash M: TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol. 2004, 4: 675-687.PubMed

222.

Pitcher LA, van Oers NS: T-cell receptor signal transmission: who gives an ITAM?. Trends Immunol. 2003, 24: 554-560.PubMed

223.

Gastman BR, Johnson DE, Whiteside TL, Rabinowich H: Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. Blood. 2000, 95: 2015-2023.PubMed

224.

Boussiotis VA, Barber DL, Lee BJ, Gribben JG, Freeman GJ, Nadler LM: Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation. J Exp Med. 1996, 184: 365-376.PubMed

225.

Kim CW, Choi SH, Chung EJ, Lee MJ, Byun EK, Ryu MH, Bang YJ: Alteration of signal-transducing molecules and phenotypical characteristics in peripheral blood lymphocytes from gastric carcinoma patients. Pathobiology. 1999, 67: 123-128.PubMed

226.

Reichert TE, Day R, Wagner EM, Whiteside TL: Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res. 1998, 58: 5344-5347.PubMed

227.

Zea AH, Curti BD, Longo DL, Alvord WG, Strobl SL, Mizoguchi H, Creekmore SP, O'Shea JJ, Powers GC, Urba WJ: Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res. 1995, 1: 1327-1335.PubMed

228.

Healy CG, Simons JW, Carducci MA, DeWeese TL, Bartkowski M, Tong KP, Bolton WE: Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry. 1998, 32: 109-119.PubMed

229.

Mulder WM, Bloemena E, Stukart MJ, Kummer JA, Wagstaff J, Scheper RJ: T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut. 1997, 40: 113-119.PubMedCentralPubMed

230.

Muller D, Lang S, Roskrow M, Wollenberg B: [The expression of zeta-chain of the T cell receptor as prognostic marker for patients with head and neck cancer]. Laryngorhinootologie. 2002, 81: 516-520.PubMed

231.

Whiteside TL: Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer?. Cancer Immunol Immunother. 2004, 53: 865-878.PubMed

232.

Eleftheriadis T, Kartsios C, Yiannaki E, Antoniadi G, Kazila P, Pliakos K, Liakopoulos V, Markala D: Decreased CD3+CD16+ natural killer-like T-cell percentage and zeta-chain expression accompany chronic inflammation in haemodialysis patients. Nephrology (Carlton). 2009, 14: 471-475.

233.

Eleftheriadis T, Kartsios C, Yiannaki E, Kazila P, Antoniadi G, Liakopoulos V, Markala D: Chronic inflammation and CD16+ natural killer cell zeta-chain downregulation in hemodialysis patients. Blood Purif. 2008, 26: 317-321.PubMed

234.

Nambiar MP, Krishnan S, Warke VG, Tsokos GC: TCR zeta-chain abnormalities in human systemic lupus erythematosus. Methods Mol Med. 2004, 102: 49-72.PubMed

235.

Takeuchi T, Tsuzaka K, Abe T, Yoshimoto K, Shiraishi K, Kameda H, Amano K: T cell abnormalities in systemic lupus erythematosus. Autoimmunity. 2005, 38: 339-346.PubMed

236.

Berg L, Ronnelid J, Klareskog L, Bucht A: Down-regulation of the T cell receptor CD3 zeta chain in rheumatoid arthritis (RA) and its influence on T cell responsiveness. Clin Exp Immunol. 2000, 120: 174-182.PubMedCentralPubMed

237.

Maurice MM, Lankester AC, Bezemer AC, Geertsma MF, Tak PP, Breedveld FC, van Lier RA, Verweij CL: Defective TCR-mediated signaling in synovial T cells in rheumatoid arthritis. J Immunol. 1997, 159: 2973-2978.PubMed

238.

Ammirati E, Vermi AC, Cianflone D, Banfi M, Foglieni C, Godino C, Airoldi F, Ferri LA, Gorman CL, Manfredi AA: Expansion of T-cell receptor zeta dim effector T cells in acute coronary syndromes. Arterioscler Thromb Vasc Biol. 2008, 28: 2305-2311.PubMed

239.

Sikora J, Dworacki G, Giersz R, Zeromski J: The role of monocytes/macrophages in TCR-zeta chain downregulation and apoptosis of T lymphocytes in malignant pleural effusions. J Biol Regul Homeost Agents. 2004, 18: 26-32.PubMed

240.

Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G, Lambris JD: Modulation of the antitumor immune response by complement. Nat Immunol. 2008, 9: 1225-1235.PubMedCentralPubMed

241.

Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, Padhya T, McCaffrey TV, McCaffrey JC, Gabrilovich DI: Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol. 2009, 182: 5693-5701.PubMedCentralPubMed

242.

Choi JY, Oughton JA, Kerkvliet NI: Functional alterations in CD11b(+)Gr-1(+) cells in mice injected with allogeneic tumor cells and treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Int Immunopharmacol. 2003, 3: 553-570.PubMed

243.

Makarenkova VP, Bansal V, Matta BM, Perez LA, Ochoa JB: CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol. 2006, 176: 2085-2094.PubMed

244.

Ezernitchi AV, Vaknin I, Cohen-Daniel L, Levy O, Manaster E, Halabi A, Pikarsky E, Shapira L, Baniyash M: TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J Immunol. 2006, 177: 4763-4772.PubMed

245.

Schmielau J, Finn OJ: Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 2001, 61: 4756-4760.PubMed

246.

Nambiar MP, Fisher CU, Enyedy EJ, Warke VG, Kumar A, Tsokos GC: Oxidative stress is involved in the heat stress-induced downregulation of TCR zeta chain expression and TCR/CD3-mediated [Ca(2+)](i) response in human T-lymphocytes. Cell Immunol. 2002, 215: 151-161.PubMed

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Myocardium-derived conditioned medium improves left ventricular function in rodent acute myocardial infarction

The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease

In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2

Induction of Th1Immune responses following laser ablation in a murine model of colorectal liver metastases